ARV-471 (PF-07850327) is being evaluated against fulvestrant in patients with ER+/HER2- advanced breast cancer who have progressed after prior endocrine therapy. The market for advanced breast cancer therapies is significant, with a growing demand for innovative treatments that offer improved efficacy and safety profiles. Fulvestrant is an established therapy, but ARV-471's unique mechanism as a PROTAC may provide a competitive edge. The successful outcome of this trial could position Pfizer favorably in the oncology market, particularly in the context of increasing competition from other SERDs and novel endocrine therapies. Diligence should focus on the trial's primary and secondary endpoints, as well as the potential for regulatory approval timelines and market access strategies.